Enovis (ENOV) Stock Price, News & Analysis

Company Overview

Enovis Corporation is a medical technology company that develops, manufactures and distributes products designed to improve patient outcomes and support the restoration of movement. Its portfolio serves orthopedic, rehabilitation and recovery markets, with products used by physicians, hospitals, physical therapists, athletic trainers and consumers.

The company’s offerings include orthopedic braces and supports, cold and compression therapy systems, rehabilitation equipment, electrical stimulation and ultrasound products, surgical implants and related technologies. Enovis markets products under established brands including DJO, Aircast, Chattanooga and Mueller, among others.

Enovis was formed through the transformation of Colfax Corporation and adopted its current name in 2022 after the separation of Colfax’s fabrication technology business, which became ESAB Corporation. The company serves customers in North America, Europe and other international markets through direct sales, distributors and healthcare channels. Mark Thierer serves as president and chief executive officer.

Key Stats

• Today's Range: $17.67 to $18.27
• 50-Day Range: $17.72 to $31.42
• 52-Week Range: $17.30 to $34.28
• Volume: 1.37 million shs
• Average Volume: 1.96 million shs
• Market Capitalization: $1.02 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $40.38
• Consensus Rating: Moderate Buy

Enovis Stock Analysis - MarketRank™

Enovis scored higher than 76% of companies evaluated by MarketBeat, and ranked 136th out of 888 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Enovis has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on no strong buy ratings, 10 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Enovis has a consensus price target of $40.38, representing about 127.8% upside from its current price of $17.72.

Amount of Analyst Coverage

Enovis has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: -2.22%

Earnings Growth

Earnings for Enovis are expected to decrease by -2.22% in the coming year, from $3.15 to $3.08 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Enovis is -0.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Enovis is -0.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Enovis has a P/B Ratio of 0.68. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

16.94% of the float of Enovis has been sold short.

Short Interest Ratio / Days to Cover

Enovis has a short interest ratio ("days to cover") of 3.52, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Enovis has recently increased by 4.27%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Enovis does not currently pay a dividend.

Dividend Growth

Enovis does not have a long track record of dividend growth.

News and Social Media

• Score: 1.4 / 5
• News Sentiment: N/A

News Sentiment

Enovis has a news sentiment score of 0.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.44 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Enovis this week, compared to 4 articles on an average week.

Search Interest

Only 3 people have searched for ENOV on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Enovis to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

Company Ownership

• Score: 4.4 / 5
• Insider Trading: Acquiring Shares

Cluster Insider Buying

2 insiders have purchased shares of Enovis in the last three months. Multiple insiders buying is a strong bullish signal.

Net Insider Buying

Over the last three months, insiders have purchased a net $449,599.00 in company stock, which represents 0.0440% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, Enovis insiders have bought more of their company's stock than they have sold. Specifically, they have bought $449,599.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

2.90% of the stock of Enovis is held by insiders.

Percentage Held by Institutions

98.45% of the stock of Enovis is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/06/2026
• Today: 10/05/2026
• Next Earnings (Estimated): 11/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: Healthcare Equipment
• Current Symbol: NYSE:ENOV
• CIK: 1420800
• Web: www.enovis.com
• Phone: 302-252-9160
• Fax: 301-323-9001
• Employees: 7,802
• Year Founded: 1995

Price Target and Rating

• Average Price Target for Enovis: $40.38
• High Price Target: $52.00
• Low Price Target: $27.00
• Potential Upside/Downside: +127.8%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.75
• Research Coverage: 12 Analysts

Profitability

• EPS (Trailing Twelve Months): ($19.26)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 5.63
• P/E Growth: N/A
• Net Income: -$1.18 billion
• Net Margins: -47.96%
• Pretax Margin: -46.52%
• Return on Equity: 12.03%
• Return on Assets: 4.91%

Debt

• Debt-to-Equity Ratio: 0.84
• Current Ratio: 1.98
• Quick Ratio: 1.00

Sales & Book Value

• Annual Sales: $2.25 billion
• Price / Sales: 0.45
• Cash Flow: $26.85 per share
• Price / Cash Flow: 0.66
• Book Value: $26.09 per share
• Price / Book: 0.68

Miscellaneous

• Outstanding Shares: 57,670,000
• Free Float: 55,997,000
• Market Cap: $1.02 billion
• Optionable: Optionable
• Beta: 1.37